Full Generic Medicine Info
Dosage/Direction for Use

Allergic rhinitis
Adult: As 0.05% susp: 100 mcg into each nostril once daily, increased to 200 mcg into each nostril daily if needed.
Child: 3-11 yr 50 mcg into each nostril once daily; ≥12 yr Same as adult dose.

Nasal polyps
Adult: 100 mcg into each nostril once daily, increased to bid after 5-6 wk if needed.

Asthma prophylaxis
Adult: As dry powd inhaler: Mild to moderate: Initially, 400 mcg once daily in the evening. Maintenance dose: 200 mcg 1-2 times daily. Severe: Initially, 400 mcg bid, titrated to the lowest effective dose once symptoms are controlled.
Child: ≥12 yr Same as adult dose.

Corticosteroid-responsive dermatoses
Adult: As 0.1% cream/oint: Apply a thin film to affected area once daily. As 0.1% lotion: Apply a few drops to affected area once daily, massage lightly until it disappears.
Child: ≥2 yr As 0.1% cream/oint: Apply a thin film to affected area once daily for not more than 3 wk. ≥12 yr As 0.1% lotion: Same as adult dose.
Special Precautions
Patient w/ heart failure, DM, GI disorders, myasthenia gravis, acute MI, cataracts/glaucoma, thyroid disease; history of seizure disorders; untreated localised infection of the nasal mucosa (e.g. herpes simplex), recent nasal surgery/trauma; patient w/ or at risk of osteoporosis. Patient w/ facial rosacea, acne vulgaris, skin atrophy, perioral dermatitis, perianal/genital pruritis, napkin eruptions; bacterial, viral, parasitical and fungal infections; varicella, syphilis or post-vaccine reactions. Avoid abrupt withdrawal when switching from systemic to oral or orally inhaled corticosteroid. Hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor pulmonary function, signs/symptoms of candidiasis, ocular effects.
Adverse Reactions
Hypothalmic-pituitary-adrenal (HPA) axis suppression, immunosuppression, Kaposi sarcoma, oral candidiasis, psychiatric disturbances, headache, allergic rhinitis, pharyngitis, upper resp tract infection, sinusitis, dysmenorrhoea, musculoskeletal pain, back pain, dyspepsia, myalgia, abdominal pain, nausea.
Potentially Fatal: Paradoxical bronchospasm, anaphylaxis.
Symptoms: Suppression of hypothalamic-pituitary-adrenal (HPA) function resulting in secondary adrenal insufficiency. Management: Gradually reduce dose.
Drug Interactions
Strong CYP3A4 inhibitors (e.g. ketoconazole) may increase systemic exposure of mometasone.
Mometasone depresses the formation, release and activity of endogenous inflammatory chemical mediators (e.g. kinins, histamine, liposomal enzymes and prostaglandin). It inhibits the margination and subsequent cell migration to the injury site, reverses vascular dilatation and permeability, resulting in decreased access of cells to the area of injury.
Onset: Inhalation: ≥1-2 wk.
Absorption: Poorly absorbed (<1%) after inhalation, intranasal use and topical application. Time to peak plasma concentration: 0.5-2.5 hr (inhalation).
Distribution: Volume of distribution: 152 L. Plasma protein binding: 98-99%.
Metabolism: Undergoes hepatic metabolism by CYP3A4 isoenzyme.
Excretion: Via faeces and urine (lesser extent). Terminal elimination half-life: Approx 5 hr.
Inhalation: Store between 20-25°C. Protect from heat or open flame. Nasal: Store at 25°C. Protect from light. Topical/Cutaneous: Store between 2-30°C.
CIMS Class
Antiasthmatic & COPD Preparations / Nasal Decongestants & Other Nasal Preparations / Topical Corticosteroids
ATC Classification
D07AC13 - mometasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
D07XC03 - mometasone ; Belongs to the class of potent (group III) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
R03BA07 - mometasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
R01AD09 - mometasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
Disclaimer: This information is independently developed by CIMS based on mometasone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in